홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Xylazine

HCID 5707
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
7361-61-7
표준 SMILES
Cc1cccc(C)c1NC1=NCCCS1
InChIKey
BPICBUSOMSTKRF-UHFFFAOYSA-N
분자식
C12H16N2S
평균 분자량
220.34 g/mol
단동위원소 질량
220.10341969

개요

Xylazine is a methyl benzene that is 1,3-dimethylbenzene which is substituted by a 5,6-dihydro-4H-1,3-thiazin-2-ylnitrilo group at position 2. It is an alpha2 adrenergic receptor agonist and frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties. It has a role as an emetic, an analgesic, an alpha-adrenergic agonist, a sedative and a muscle relaxant. It is a methylbenzene, a 1,3-thiazine and a secondary amino compound. It is a conjugate base of a xylazine(1+).

이름 및 식별자

우선 이름
Xylazine
IUPAC
N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine
영어명
Xylazine
분자식
C12H16N2S
분자량
220.33

이름 및 동의어

xylazine7361-61-7N-(2,6-Dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amineXilazinaChanazineXylazinXylazinumBAY 1470WH 72865,6-Dihydro-2-(2,6-xylidino)-4H-1,3-thiazine4H-1,3-Thiazin-2-amine, N-(2,6-dimethylphenyl)-5,6-dihydro-2-(2,6-Dimethylanilino)-5,6-dihydro-4H-1,3-thiazine
이름 더 보기
Xylazine (free base)wh7286bay1470Mobay RompunXylazine (CRM)Xylazine, >=99%
DTXSID30406432-(2,6-Dimethylphenylamino)-4H-5,6-dihydro-1,3-thiazine2KFG9TP5V8NSC-758142CHEBI:92386DTXCID1020643XylaxineRefChem:56228

데이터베이스 식별자

CAS
7361-61-7
PubChem CID
5707
DTXSID
DTXSID3040643
ChEMBL
CHEMBL297362
ChEBI
CHEBI:92386
UNII
2KFG9TP5V8

물성

구조 계산 물성

XLogP
2.8
극성 표면적
49.7 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
2
회전 가능 결합 수
2
무거운 원자 수
15
형식 전하
0
복잡도
230

실험 및 물리화학적 성질

Drugs · 2건

DEA NFLIS-Drug Category -> Depressants and Tranquilizers

Pharmaceuticals -> Listed in ZINC15

LogP1.34
Animal Drugs · 3건

FDA approved animal drugs -> Active ingredient

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Collision Cross Section · 5건

147.9 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

148.6 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

147.8 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

147.16 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

148.72 Ų [M+H]+

물리화학적 성질

녹는점
140 C · 140 C
끓는 점
334.2 · 334.2±52.0 °C(Predicted)
밀도
1.0905 · 1.0905 (rough estimate)
굴절률
1.57 · 1.5700 (estimate)
저장 조건
-20 °C · -20°C
용해도
50 mg/ml의 · 50mg/ml의 메탄올에 용해됩니다. 묽은 산성 용액에도 용해됩니다.

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H301 (98.1%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 54 reports by companies from 6 notifications to the ECHA C&L Inventory.

유해성 정보

Regulatory InformationXylazine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - 4H-1,3-Thiazin-2-amine, N-(2,6-dimethylphenyl)-5,6-dihydro-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (98.1%)

독성 정보

Exposure RoutesIIntravenous (IV) administration was a common route for Xylazine as noted in case reports. Other routes included subcutaneous (SC), intramuscular (IM), and inhalation, with overall doses ranging from 40 mg to 4300 mg in humans.
Toxicity Summary · 2건

Xylazine use can cause drowsiness, abnormally slow or absent breathing, low blood pressure, and a slow heart rate. A coma can develop and require the insertion of a breathing tube and hospitalization. The overdoes signs and symptoms are similar to those of heroin, fentanyl, and other opioids. If xylazine is added to opioids, severe toxicity and death can occur due to the combined effects of the drugs. Withdrawal can occur in people who abruptly discontinue use, and can result in markedly elevated blood pressure, rapid heart rate, and agitation. Headaches, insomnia, and nausea can also occur during withdrawal.

화학 및 산업

약리 정보

ATC CodeQN - Nervous system
MeSH Pharmacological Classification · 4건

Compounds capable of relieving pain without the loss of CONSCIOUSNESS.

Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.

A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)

Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS.

용도 및 제조

Consumer Uses · 2건

Xylazine is available for veterinary usage for injection in concentrations of 20 mg/mL, 100 mg/mL, and 300 mg/mL. The solution may be dried into a powder or salted. Xylazine may be added to other illicit substances for many reasons.

Xylazine is an animal tranquilizer used to provide sedation, pain relief, and muscle relaxation. It was initially studied in humans as a potential blood pressure-lowering drug; however, it was found to cause excessive sleepiness. Currently, xylazine is not approved for human use by the U.S. Food and Drug Administration. Xylazine was initially discovered as an illicit drug contaminant in the U.S. in the early 2000s, e.g., it has been found in cocaine, heroin, and fentanyl.

Use Classification · 2건

Veterinary Drug -> ADRENOCEPTOR_AGONIST -> JECFA Functional Classes

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

응용 분야 · 3건

관련 반응

25건
반응 기록 만들기
HRID 12014 반응식
HRID 12014반응물로
HRID 65475 반응식
HRID 65475생성물로
HRID 892129 반응식
HRID 892129반응물로
HRID 1078539 반응식
HRID 1078539반응물로
HRID 1454323 반응식
HRID 1454323반응물로
HRID 1477068 반응식
HRID 1477068반응물로
HRID 1477069 반응식
HRID 1477069반응물로
HRID 1477070 반응식
HRID 1477070반응물로
이전1 / 4 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
EC Number
230-902-1
Nikkaji
J8.925G
산도 계수 (pKa)
7.67 · 7.67±0.20(Predicted)
물리적 상태
가루
색상
White
InChI
InChI=1S/C12H16N2S/c1-9-5-3-6-10(2)11(9)14-12-13-7-4-8-15-12/h3,5-6H,4,7-8H2,1-2H3,(H,13,14)
InChIKey
BPICBUSOMSTKRF-UHFFFAOYSA-N
SMILES
S1CCCN=C1NC1=C(C)C=CC=C1C

Acute xylazine exposure can lead to severe central nervous system (CNS) depression, respiratory depression, bradycardia, hypotension, and, in extreme cases, cardiac arrest. Long-term use of xylazine-mixed illicit substances can result in cumulative toxic effects, e.g., chronic wounds and ulcers on the skin. The primary metabolite of xylazine, 2,6-xylidine, has carcinogenic and genotoxic effects, and long-term users of xylazine appear to be at increased risk for malignancies. There are no human data on the effect of xylazine on embryogenesis and pregnancy. Studies have found increased uterine contractions, decreased uterine blood flow, and fetal loss when used in pregnant cattle and goats.

Antidote and Emergency Treatment · 1건

Identification of xylazine toxicity is difficult due to its use as an adulterant and possible polysubstance use. Identifying xylazine toxicity based on history and physical examination is challenging since other substances and their toxidromes may be present. The authors of this publication suggest having a low threshold of suspicion for coadministration of xylazine and any available illicit drug. Xylazine toxicity by itself is characterized by CNS depression. Symptoms may include a "high" feeling, sedation, dry mouth, dysarthria, hyporeflexia, disorientation, dysmetria, miosis, hypotension, bradycardia, hypothermia, and hyperglycemia. Xylazine combined with other CNS depressants such as opioids, benzodiazepines, or alcohol can cause severe CNS depression with signs and symptoms of obtundation, coma, muscle relaxation, hypotension or hypertension, respiratory depression, areflexia, asthenia or apnea, cardiac arrhythmias or cardiac arrest. As of June 2023, no pharmacological antidote for xylazine intoxication has been approved by the United States Food and Drug Administration (FDA). Management of xylazine intoxication involves supportive care, monitoring for adverse effects, and interventional management as symptoms present. The few studies on humans and animals indicate potentially life-threatening complications of xylazine use, including biventricular failure, pulmonary edema, cardiac necrosis, valvular dysfunction, and insulin-dependent diabetes mellitus.

Human Toxicity Values · 1건

The doses in case reports ranged from 40 mg to 4300 mg in humans. The average dose in fatal cases was 1,200 mg, compared to 525 mg in non-fatal cases. Concurrent administration of other drugs, primarily opioids, occurred in 28 cases (47.5%).

안전 데이터

wgk
3
rtecs
XJ0776300
ridadr
UN 2811 6.1/PG 3
독성
LD50 in mice (mg/kg): 43 i.v.; 121 s.c.; 240 orally; LD50 in rats (mg/kg): 130 orally (Sagner)
HS 번호
2934990002
risk_code
25-36/37/38
hazard_code
T,Xi
safety_code
45-37/39-26
위험 등급
6.1
Hazard Classifications
Acute Tox. 3 Oral
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

개요Xylazine is an agonist of α2-adrenergic receptors (Ki = 194 nM). It is an analog of clonidine, an α2-adrenergic receptor agonist used to reduce blood pressure. Xylazine is used for sedation, anesthesia, and analgesia in non-human mammals. This product is also available as an analytical reference standard .

용도Xylazine is an α2 class of adrenergic receptor agonist. Xylazine is a clonidine analoque that acts on presynaptic and postsynaptic receptors as an a 2-adrenergic agonist.

일반 설명Xylazine is soluble in methanol (50 mg/ml), yielding a clear, colorless solution. It is also soluble in dilute HCl acid and in chloroform. Xylazine is practically insoluble in water and in alkali solutions.

상·하류 제품 정보

상류 원료

3-아미노프로판올수산화나트륨염산티오포스겐